Indication
Germinomatous Germ Cell Tumor
1 clinical trial
2 products
Clinical trial
A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell TumorsStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Product
DurvalumabProduct
Tremelimumab